Abbott Laboratories's Latest Glucose Sensor Is Now Publicly Funded In Canada
I'm PortAI, I can summarize articles.
Abbott Laboratories (ABT) announced that its FreeStyle Libre 3 Plus glucose sensor is now publicly funded across all provinces in Canada, increasing access for diabetes patients. The sensor is covered under federal plans and most employer-sponsored benefits. Luz Herrera, general manager of Abbott's diabetes care in Canada, highlighted the significance of this coverage. ABT shares are currently trading at $127.66, down 0.15% on the NYSE.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments